# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-22
**æ›´æ–°æ—¶é—´**: 2026-01-23 03:41
**æ–°é—»æ•°é‡**: 102

---

## ä»Šæ—¥æ¦‚è§ˆ

## ðŸ“Š AI æ™ºèƒ½åˆ†æž

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šå‘ˆçŽ°å¤šå…ƒåŒ–åŠ¨æ€ï¼Œç›‘ç®¡æ”¿ç­–ä¸Žé‡å¤§å•†ä¸šäº¤æ˜“æˆä¸ºç„¦ç‚¹ã€‚FDAå‘å¸ƒå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å¼€å‘æ–°æŒ‡å—ï¼Œæœ‰æœ›åŠ é€Ÿç›¸å…³ç–—æ³•å®¡æ‰¹ï¼›GSKä»¥22äº¿ç¾Žå…ƒæ”¶è´­RAPT Therapeuticsï¼Œå¼ºåŒ–è¿‡æ•é¢†åŸŸå¸ƒå±€ï¼›åŒæ—¶ï¼Œç”Ÿç‰©ç±»ä¼¼è¯å¸‚åœºå‰æ™¯ä¹è§‚ï¼Œè€ŒValnevaå› å®‰å…¨æ€§é—®é¢˜æ’¤å›žåŸºå­”è‚¯é›…çƒ­ç–«è‹—ã€‚

### ðŸ”¥ é‡ç‚¹æ–°é—»

**4. J&J praises new FDA guidance to speed development of multiple myeloma drugs** â­â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - FDAå‘å¸ƒæ–°æŒ‡å—ï¼Œå…è®¸ä½¿ç”¨å¾®å°æ®‹ç•™ç—…ä½œä¸ºä¸»è¦ç»ˆç‚¹ï¼Œå¯èƒ½åŠ é€Ÿå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å®¡æ‰¹ï¼Œå¯¹è¡Œä¸šç ”å‘è·¯å¾„æœ‰é‡å¤§å½±å“ã€‚

**17. GSK to buy Rapt in $2.2B deal for food allergy drug** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - GSKä»¥22äº¿ç¾Žå…ƒæ”¶è´­RAPT Therapeuticsï¼ŒèŽ·å¾—å®žéªŒæ€§é£Ÿç‰©è¿‡æ•è¯ç‰©ï¼Œæ˜¯CEOä¸Šä»»åŽé¦–ç¬”é‡å¤§äº¤æ˜“ï¼Œæˆ˜ç•¥æ„ä¹‰æ˜¾è‘—ã€‚

**8. Biosimilar execs optimistic about future for US biosims as Sandoz locks in on â€˜golden decadeâ€™ to come** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æž
   - FDAæ–°æŒ‡å—ç®€åŒ–ç”Ÿç‰©ç±»ä¼¼è¯å¼€å‘ï¼Œè¡Œä¸šé«˜ç®¡å¯¹å¸‚åœºå‰æ™¯ä¹è§‚ï¼Œé¢„ç¤ºç”Ÿç‰©ç±»ä¼¼è¯å¯èƒ½è¿›å…¥å¿«é€Ÿå¢žé•¿æœŸã€‚

**12. Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - Valnevaå› FDAè°ƒæŸ¥æ–°çš„ä¸¥é‡ä¸è‰¯ååº”è€Œè‡ªæ„¿æ’¤å›žåŸºå­”è‚¯é›…çƒ­ç–«è‹—ï¼Œå‡¸æ˜¾ç–«è‹—å®‰å…¨æ€§ç›‘ç®¡çš„é‡è¦æ€§ã€‚

**1. Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æž
   - ä¸‰æ˜Ÿç”Ÿç‰©åˆ¶å‰‚æˆä¸ºé¦–å®¶å¹´åˆ©æ¶¦çªç ´2ä¸‡äº¿éŸ©å…ƒçš„éŸ©å›½ç”Ÿç‰©åˆ¶è¯å…¬å¸ï¼Œæ˜¾ç¤ºCDMOè¡Œä¸šå¼ºåŠ²å¢žé•¿å’Œé¾™å¤´åœ°ä½ã€‚

### ðŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): IntraBioçš„Aqneursaåœ¨ç½•è§ç—…é¢†åŸŸå–å¾—IIIæœŸæˆåŠŸï¼Œå¹¶èŽ·æ¬§ç›Ÿæ‰¹å‡†ï¼›Corvusçš„æ¹¿ç–¹å£æœè¯æ—©æœŸæ•°æ®ç§¯æžï¼›DefiniumæŽ¨è¿›LSDè¯ç‰©æ²»ç–—ç²¾ç¥žå¥åº·é€‚åº”ç—‡ï¼›CorxelèŽ·å¾—2.87äº¿ç¾Žå…ƒèžèµ„å¼€å‘å£æœGLP-1å‡è‚¥è¯ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): IntraBioå®£å¸ƒå…¶æ²»ç–—å…±æµŽå¤±è°ƒ-æ¯›ç»†è¡€ç®¡æ‰©å¼ ç—‡çš„è¯ç‰©åœ¨å…³é”®IIIæœŸè¯•éªŒä¸­æ”¹å–„è¿åŠ¨åŠŸèƒ½ï¼Œå°†å¯»æ±‚FDAæ‰¹å‡†ï¼›CEPIèµ„åŠ©3000ä¸‡ç¾Žå…ƒä¸Žé»˜å…‹ç­‰åˆä½œæ”¹è¿›åŸƒåšæ‹‰ç–«è‹—ã€‚

### ðŸ”® æ˜Žæ—¥å…³æ³¨

å…³æ³¨FDAå¯¹Valnevaç–«è‹—å®‰å…¨è°ƒæŸ¥çš„è¿›å±•ã€GSKæ”¶è´­RAPTçš„åŽç»­æ•´åˆã€ä»¥åŠFDAæ–°æŒ‡å—å¯¹å¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©ç ”å‘çš„å®žé™…å½±å“ã€‚åŒæ—¶ï¼Œç•™æ„å›½ä¼šå¯èƒ½é€šè¿‡çš„PBMæ”¹é©æ³•æ¡ˆå’Œæ”¿åºœèµ„åŠ©æ³•æ¡ˆä¸­çš„åŒ»è¯ç›¸å…³æ”¿ç­–ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 40 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## ç»¼åˆ | ç»¼åˆ

### ðŸ‡ºðŸ‡¸ Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 07:36
- **é‡è¦æ€§**: â­â­â­â­

> CDMO Samsung Biologics grew sales more than 30% last year to around 4.6 trillion Korean won ($3.1 billion) and lifted its 2025 operating profit to roughly 2.07 trillion won ($1.4 billion). Samsung Bio is now the first Korean biotech or pharmaceutical company to surpass the 2 trillion won annual profit threshold, local news outlets reported this week.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/samsung-bio-sticks-landing-2025-it-becomes-first-korean-biopharma-hit-2-trillion-won-profit)

---

### ðŸ‡ºðŸ‡¸ Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:29
- **é‡è¦æ€§**: â­â­â­â­

> Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSKâ€™s ViiV Healthcare. The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms of the agreement, Shionogi will pick up Pfizerâ€™s shares for $2.125 billion, with GSK gaining a special dividend of $250 million.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/pfizer-sells-its-stake-gsks-viiv-19b-shionogi-upping-its-ante-hiv-focused-company)

---

### ðŸ‡ºðŸ‡¸ CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:54
- **é‡è¦æ€§**: â­â­â­

> The project, which involves Merck, SK Bioscience, Hilleman Laboratories and CDMO IDT Biologika, aims to make Merck's current Ebola vaccine easier to manufacture and store, prompting broader global accessibility.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/cepi-bankrolls-30m-ebola-vaccine-collaboration-merck-sk-biosciences-and-others)

---

### ðŸ‡ºðŸ‡¸ IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 11:04
- **é‡è¦æ€§**: â­â­â­

> The company announced a phase 3 win in the rare neurodegenerative disease Ataxia-telangiectasia on the same day it snagged a key European approval in the drug's original indication of Niemann-Pick disease type C.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win)

---

### ðŸ‡ºðŸ‡¸ Biosimilar execs optimistic about future for US biosims as Sandoz locks in on â€˜golden decadeâ€™ to come

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 17:07
- **é‡è¦æ€§**: â­â­

> Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming â€œbiosimilar void.â€

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/biosimilar-execs-remain-optimistic-state-us-biosimilars-while-sandoz-locks-golden-decade)

---

### ðŸ‡ºðŸ‡¸ Led by Darzalex surge, J&amp;J expects revenue to reach $100B in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 11:20
- **é‡è¦æ€§**: â­â­

> Led by cancer standout Darzalex, Johnson &amp; Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&amp;J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026)

---

### ðŸ‡ºðŸ‡¸ Definium defines mental health applications for LSD in new awareness campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:30
- **é‡è¦æ€§**: â­â­

> As it inches closer to FDA submissions for its psychedelic drug candidate, Definium Therapeutics is laying the groundwork for a future launch with an educational push about the pharmaceutical potential of LSD.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/definium-defines-mental-health-applications-lsd-new-awareness-campaign)

---

### ðŸ‡ºðŸ‡¸ Roche scales Genentech's North Carolina site to $2B in major obesity market play

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:47
- **é‡è¦æ€§**: â­â­

> Roche is more than doubling its total commitment to a future facility for its Genentech unit to approximately $2 billion. The plant, being built in Holly Springs, North Carolina, will be used to crank out next-generation drugs for metabolic conditions like obesity, Roche has said.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/roche-beefs-investment-genentechs-future-nc-obesity-drug-factory-2b)

---

### ðŸ‡ºðŸ‡¸ Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:53
- **é‡è¦æ€§**: â­â­

> Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S. The FDA has also opened an investigation into a newly reported serious adverse event.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/valneva-withdraws-chikungunya-vaccine-ixchiq-us-amid-new-fda-investigation)

---

### ðŸ‡ºðŸ‡¸ STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 17:40
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:14
- **é‡è¦æ€§**: â­â­

> Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 08:01
- **é‡è¦æ€§**: â­â­

> GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: FDA delays reviews for two drugs in new voucher program

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:36
- **é‡è¦æ€§**: â­â­

> And more biotech news, brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:30
- **é‡è¦æ€§**: â­â­

> Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines over possible legal risks

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 15:19

> While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius)

---

### ðŸ‡ºðŸ‡¸ Invivyd teams up with Olympic skier Lindsey Vonn for antibody education

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:54

> As Lindsey Vonnâ€™s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/invivyd-teams-olympic-skier-lindsey-vonn-antibody-education)

---

### ðŸ‡ºðŸ‡¸ Lundbeck â€˜not willing to compromiseâ€™ on M&amp;A strategy after missed Avadel attempt: exec

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:23

> Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that itâ€™s not desperate for deals and will not lower its standards for future M&amp;A transactions.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/lundbeck-not-willing-compromise-ma-strategy-after-missed-avadel-attempt)

---

### ðŸ‡ºðŸ‡¸ Trump's Davos drug pricing claims decried as 'fake news' by French presidency

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 09:57

> After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his tariff-tinged trade negotiations, the French presidency has pushed back against a drug pricing claim that itâ€™s branding â€œfake news.â€

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/trumps-davos-drug-pricing-claims-decried-fake-news-french-presidency)

---

### ðŸ‡ºðŸ‡¸ In J&amp;J talc litigation, N.J. court-appointed official recommends allowing expert testimony

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 15:13

> In Johnson &amp; Johnson's long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company's defense of lawsuits from those who claim Johnsonâ€™s Baby Powder caused their cancer.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/jj-talc-litigation-nj-court-recommends-allow-expert-testimony)

---

### ðŸ‡ºðŸ‡¸ UPDATE: In quick reversal, Trump calls off tariff threat related to Greenland pursuit

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:55

> Only a few days after threatening to impose new tariffs on a group of European countries related to his pursuit of Greenland, the president has called off the threat.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal)

---

### ðŸ‡ºðŸ‡¸ Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 09:46

> While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizerâ€™s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/pfizer-ceo-lays-blame-us-vaccine-woes-anti-science-rfk-jr-wsj)

---

### ðŸ‡ºðŸ‡¸ Rising Stars: Regeneronâ€™s Catie Matthews on updating marketing strategy to meet the AI boom

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 12:30

> In a Q&amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Catie Matthews suggested that marketers should embrace artificial intelligence in their own lives.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/rising-stars-regenerons-catie-matthews-updating-marketing-strategy-amid-ai-boom)

---

### ðŸ‡ºðŸ‡¸ GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 14:08

> GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotechâ€™s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact)

---

### ðŸ‡ºðŸ‡¸ Takeda's neuroscience field force hit with layoffs as key patent loss looms for Trintellix

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 13:14

> Takeda is executing another round of layoffs, cutting 243 roles in the U.S. The company is preparing for an upcoming patent loss on depression drug Trintellix.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix)

---

### ðŸ‡ºðŸ‡¸ Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:27

> The U.S. Supreme Court will hear a case involving the "skinny label" practice of generic drug makers, with its review particularly relating to Hikma's marketing of its generic version of Amarin's Vascepa.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/supreme-court-agrees-review-skinny-label-battle-hikma-amarin-over-generic-vascepa)

---

### ðŸ‡ºðŸ‡¸ Curia's Mass. plant closure to eliminate 81 jobs

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 17:08

> Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing facility in Burlington, Massachusetts, according to a Worker Adjustment and Retraining Notification.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/curia-plant-shutdown-massachusetts-forces-lay-81)

---

### ðŸ‡ºðŸ‡¸ Apiject signs lease for new generics blow-fill-seal manufacturing facility in N.C.

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 08:33

> Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/apiject-signs-lease-new-generics-blow-fill-seal-facility-north-carolina)

---

### ðŸ‡ºðŸ‡¸ Novo riffs on Appleâ€™s â€˜Get a Macâ€™ ads in Ozempic push starring Justin Long, John Hodgman

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 15:28

> Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find inspiration for its latest direct-to-consumer Ozempic campaign.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/novo-riffs-apples-get-mac-ads-ozempic-push-starring-justin-long-john-hodgman)

---

### ðŸ‡ºðŸ‡¸ STAT+: Health insurance execs shift blame for costly, confusing health care system

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 20:11

> Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: France rebuffs Trump over drug-pricing boast

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 15:58

> And more biotech news from The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 14:26

> Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 09:30

> Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Novo strikes deal for diabetes cell therapies

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:53

> And other biotech news, brought to you by The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ Congress revives health care deal with PBM reforms

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 15:31

> This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:47

> And other biotech news brought to you by the Readout Newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:20

> U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 09:30

> In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 01:03

> Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 21:03

> The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 17:00

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ðŸ‡ºðŸ‡¸ Another biopharma tried buying Amicus before BioMarin's $4.8B deal

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:16
- **é‡è¦æ€§**: â­â­â­â­

> The road to Amicus Therapeuticsâ€™ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs and a months-long push to settle a ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/)

---

### ðŸ‡ºðŸ‡¸ J&J praises new FDA guidance to speed development of multiple myeloma drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 18:35
- **é‡è¦æ€§**: â­â­â­â­

> Johnson &amp; Johnson, which has several drugs approved for multiple myeloma, praised the FDA's just-released draft guidance on how the agency will allow the use of minimal residual disease as a primary endpoint for accelerated ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/jj-praises-new-fda-guidance-to-speed-development-of-multiple-myeloma-drugs/)

---

### ðŸ‡ºðŸ‡¸ IntraBio says rare disease drug passes Phase 3, will seek FDA approval

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:05
- **é‡è¦æ€§**: â­â­â­

> IntraBio said Wednesday that its treatment improved motor function for a rare genetic disorder called ataxia-telangiectasia as part of a pivotal study. The Austin, TX-based biotech told Endpoints News it plans to submit an application ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/intrabio-says-rare-disease-drug-passes-phase-3-will-seek-fda-approval/)

---

### ðŸ‡ºðŸ‡¸ Investors load Corxel with $287M for a â€˜differentiatedâ€™ obesity pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 19:00
- **é‡è¦æ€§**: â­â­

> The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/corxel-oral-glp1-vincentage-series-d-china-deal/810242/)

---

### ðŸ‡ºðŸ‡¸ FDA lays out new path to speed development of multiple myeloma drugs

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 16:36
- **é‡è¦æ€§**: â­â­

> In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.&nbsp;

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/fda-multiple-myeloma-accelerated-approval-pathway/810219/)

---

### ðŸ‡ºðŸ‡¸ Corvus shares nearly triple on positive data for eczema pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 16:39
- **é‡è¦æ€§**: â­â­

> While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/corvus-soquelitinib-phase-1-data-eczema-pill/810080/)

---

### ðŸ‡ºðŸ‡¸ Valneva to withdraw Chikungunya vaccine from US amid safety woes

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 16:47
- **é‡è¦æ€§**: â­â­

> The decision comes months after the FDA had suspended the vaccine&rsquo;s license. One analyst speculated the company might shelve the product altogether.&nbsp;

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/valneva-fda-withdrawl-application-chikungunya-Ixchiq-vaccine/809994/)

---

### ðŸ‡ºðŸ‡¸ GSK to buy Rapt in $2.2B deal for food allergy drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 15:57
- **é‡è¦æ€§**: â­â­

> The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/gsk-rapt-acquire-food-allergy-prophylaxis-drug-ozureprubart/809956/)

---

### ðŸ‡ºðŸ‡¸ Kaileraâ€™s Ron Renaud on how a China-linked startup can compete in obesity

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 12:00
- **é‡è¦æ€§**: â­â­

> In an interview with BioPharma Dive, the veteran biotech CEO said there remains a &ldquo;significant opportunity&rdquo; for young companies in a market dominated by Novo Nordisk and Eli Lilly.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/kailera-ron-renaud-obesity-hengrui-rebupatide/809798/)

---

### ðŸ‡ºðŸ‡¸ Roche boosts NC factory investment to $2B; Rentschler CEO steps down

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:39
- **é‡è¦æ€§**: â­â­

> Rocheâ€™s Genentech is topping up its investment into its Holly Springs, NC, factory to reach nearly $2 billion. The extra investment will also add an additional 100 jobs at the site ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/roche-boosts-nc-factory-investment-to-2b-rentschler-ceo-steps-down/)

---

### ðŸ‡ºðŸ‡¸ Government funding bill features PBM reforms, voucher reauthorization

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 19:14
- **é‡è¦æ€§**: â­â­

> The House is set to vote this week on a bipartisan bill to keep the government open beyond Jan. 30, with new proposals to change how pharmacy benefit managers operate and to reauthorize a lapsed ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/government-funding-bill-features-pbm-reforms-voucher-reauthorization/)

---

### ðŸ‡ºðŸ‡¸ Bristol Myers buys into Januxâ€™s â€˜maskedâ€™ T cell engagers

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 17:00
- **é‡è¦æ€§**: â­

> Worth up to $850 million, the partnership provides &ldquo;further validation&rdquo; for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.&nbsp;

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/)

---

### ðŸ‡ºðŸ‡¸ Fosun-funded Hygtia Therapeutics licenses Insilicoâ€™s NLRP3 inhibitor for Parkinsonâ€™s

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 12:14
- **é‡è¦æ€§**: â­

> A biotech funded by Shanghai Fosun Pharmaceutical is licensing a preclinical asset developed by Insilico Medicine in the NLRP3 space, which has garnered industry interest in recent months. Hygtia Therapeutics will get half the global ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/fosun-funded-hygtia-therapeutics-licenses-insilicos-nlrp3-inhibitor-for-parkinsons/)

---

### ðŸ‡ºðŸ‡¸ BioMarin vets form Mendra to â€˜modernizeâ€™ rare disease drug development

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 16:02

> Backed with $82 million and led by two of BioMarin&rsquo;s former executives, Mendra&nbsp;plans to acquire rare disease assets and use AI to help accelerate their development.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/mendra-rare-disease-biotech-startup-ai-biomarin-financing/810204/)

---

### ðŸ‡ºðŸ‡¸ J&J eyes $100B in sales amid gains for cancer, immune drugs

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 16:04

> Amid patent expirations, litigation and tariff costs, J&amp;J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/johnson-johnson-2025-earnings-sales-cancer-immune-drugs/810097/)

---

### ðŸ‡ºðŸ‡¸ Moderna cancer vaccine holds up; IO Biotech considers a sale

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 15:38

> Long-term data suggest Moderna&rsquo;s personalized melanoma shot provides &ldquo;durable tumor control,&rdquo; one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/)

---

### ðŸ‡ºðŸ‡¸ High court picked Hikmaâ€™s â€˜skinny labelâ€™ fight after letting the issue â€˜percolateâ€™

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 19:53

> Generic and brand-name drugmakers have been divided for decades over the use of â€œskinny labelsâ€ to bring lower-cost drugs to market. Now, the Supreme Court is taking up the issue. Itâ€™s wading into a case ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/high-court-picked-hikmas-skinny-label-fight-after-letting-the-issue-percolate/)

---

### ðŸ‡ºðŸ‡¸ Drugmakers spent less on Washington lobbying in 2025's final quarter

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 18:35

> The top five biopharma company spenders on congressional lobbying spent slightly less in Washington in the final quarter of 2025 than they did in the previous quarter, the latest Senate disclosures show. Pfizer and Johnson ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/drugmakers-spent-less-on-washington-lobbying-in-2025s-final-quarter/)

---

### ðŸ‡ºðŸ‡¸ Corcept's drug extends patients' lives in key ovarian cancer study

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 16:08

> Corcept Therapeutics said its experimental drug cut the risk of death by 35% for patients with a challenging form of ovarian cancer when added on top of chemotherapy, notching an important win after the California ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/corcepts-drug-extends-patients-lives-in-key-ovarian-cancer-study/)

---

### ðŸ‡ºðŸ‡¸ China-founded pharma Corxel raises up to $287M for oral GLP-1

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 16:00

> Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world. The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/china-founded-pharma-corxel-raises-up-to-287m-for-oral-glp-1/)

---

### ðŸ‡ºðŸ‡¸ Health insurance CEOs head to DC

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:39

> We donâ€™t know if President Donald Trump made good on plans to meet with major health insurers yet, but their CEOs are slated to testify today before two congressional committees ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/health-insurance-ceos-head-to-dc/)

---

### ðŸ‡ºðŸ‡¸ Bristol Myers signs deal with Janux on T cell engager for $50M upfront

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:15

> Janux Therapeutics has found a new partner. The San Diego-based biotech is teaming up with Bristol Myers Squibb on a solid tumor program, but the target is not yet disclosed. Bristol ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/bristol-myers-signs-deal-with-janux-on-t-cell-engager-for-50m-upfront/)

---

### ðŸ‡ºðŸ‡¸ Erasca, Corvus, BioAge target $500M+ offerings

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 14:43

> Plus, news about Ipsen, Galderma, PAQ Therapeutics and Resolve M Therapeutics: ðŸ’° Public offering roundup: Erasca is selling more than 22 million shares at $10 apiece, targeting $225 million in ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/erasca-corvus-bioage-target-500m-offerings/)

---

### ðŸ‡ºðŸ‡¸ #JPM26: Hua Medicine plots diabetes drug expansion in China and beyond

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 12:00

> Shanghai-based Hua Medicine wants to capture a greater share of the global diabetes market with a different approach from popular GLP-1 medicines. Many newer diabetes drugs mimic gut hormones to regulate glucose. Hua's drug for ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/hua-medicine-plots-diabetes-drug-expansion-in-china-and-beyond/)

---

### ðŸ‡ºðŸ‡¸ BioMarin vets spearhead new biotech with $82M for rare disease drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 12:00

> A fresh biotech has raised $82 million to scour the landscape of rare disease medicines that need a new home for further development and apply lessons from executives' experiences at BioMarin. The Bay Area startup ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/)

---

### ðŸ‡ºðŸ‡¸ The status of EU drug price talks depends on who you ask

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 20:33

> One of the main questions for drugmakers entering 2026, and one they hope tilts in their favor, is whether the US will successfully pressure Europe to raise the price it pays for drugs. Three weeks ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/the-status-of-eu-drug-price-talks-depends-on-who-you-ask/)

---

### ðŸ‡ºðŸ‡¸ Johnson & Johnson brushes off MFN impact, sees strong growth for 2026

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:43

> As the calendar turns from JPM to quarterly reports, earnings bellwether Johnson &amp; Johnson makes its return for 2026. The focus this time? How biopharma will react to a slate of most favored nation deals ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/)

---

### ðŸ‡ºðŸ‡¸ Tanabe pill delays blood disorder; enGene adds up to $100M from loans

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:25

> Plus, news about IO, ErVimmune, Affibody, Clasp Therapeutics and Infinitopes: ðŸ’Š Tanabe Pharmaâ€™s pill succeeds in rare blood conditions: The biotechâ€™s oral melanocortin-1 receptor delayed the onset of symptoms in a ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/tanabe-pill-delays-blood-disorder-engene-adds-up-to-100m-from-loans/)

---

### ðŸ‡ºðŸ‡¸ #JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 14:00

> There are countless diseases lacking a single good treatment, but drugmakers are still herding into the same targets, particularly in chasing after megablockbusters. George Yancopoulos, the outspoken co-founder and chief scientific officer of Regeneron, is ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/jpm26-regeneron-lilly-summit-on-rivals-crowding-into-same-targets/)

---

### ðŸ‡ºðŸ‡¸ Exclusive: Claim Health raises $4.4M to help home care providers get paid

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 14:00

> After an initial wave of AI startups that automated specific administrative tasks in healthcare, companies are now racing to handle the entire process. Claim Health, which aims to manage every step of how home care ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/exclusive-claim-health-raises-4-4m-to-help-home-care-providers-get-paid/)

---

### ðŸ‡ºðŸ‡¸ Think Bioscience gets $55M to unearth new drug pockets

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 12:00

> A Boulder, CO-based startup is searching for previously undiscovered footholds â€” not on rocks, but on molecules. Think Bioscience has raised a $55 million Series A led by investors including Regeneron Ventures ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/)

---

### ðŸ‡ºðŸ‡¸ EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 18:55

> The European Parliament has adopted proposals aimed at reducing critical drug shortages across the EU, including stricter stockpiling rules and incentives for companies to boost manufacturing capacity. On Tuesday, the European Parliament adopted the Critical ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/eu-parliament-adopts-stricter-drug-stockpiling-rules-under-critical-medicines-act/)

---

### ðŸ‡ºðŸ‡¸ Valneva withdraws chikungunya vaccine from US

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 18:37

> Valneva has taken its chikungunya vaccine out of the US market, withdrawing its suspended product and a now-halted post-marketing study. The company said Monday that it decided to voluntarily withdraw its ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/valneva-withdraws-chikungunya-vaccine-from-us/)

---

### ðŸ‡ºðŸ‡¸ Clinician groups ask court to overturn CDC's childhood vaccine overhaul

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 15:54

> Leading clinician groups are asking a federal court to undo the US overhaul of the childhood vaccine schedule, calling the move the â€œmost egregious, reckless, and dangerousâ€ action that HHS Secretary Robert F. Kennedy Jr ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/clinician-groups-ask-court-to-overturn-cdcs-childhood-vaccine-overhaul/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ðŸ‡ºðŸ‡¸ Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 17:27
- **é‡è¦æ€§**: â­â­

> Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/pharmaceutical-quality-resources/questions-and-answers-integration-fda-facility-evaluation-and-inspection-program-human-drugs-concept)

---

### ðŸ‡ºðŸ‡¸ Registered Outsourcing Facilities

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:32
- **é‡è¦æ€§**: â­â­

> Discover FDA's comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)

---

### ðŸ‡ºðŸ‡¸ Bodynplant - Online Advisory Letter

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:21
- **é‡è¦æ€§**: â­â­

> FDA Online advisory letter issued to Bodynplant/bodynplant.com for serious disease claims, including: cancer, diabetes, and HIV-AIDS

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/bodynplant-online-advisory-letter)

---

### ðŸ‡ºðŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:55
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ðŸ‡ºðŸ‡¸ Drug Trials Snapshots

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:45
- **é‡è¦æ€§**: â­â­

> Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots)

---

### ðŸ‡ºðŸ‡¸ Importing Liquid Cough and Cold Medicine from India

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 17:56
- **é‡è¦æ€§**: â­â­

> FDA is aware of news reports of devastating, ongoing diethylene glycol (DEG) and ethylene glycol (EG) contamination in childrenâ€™s cough and cold medicine in India.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/human-drug-imports/importing-liquid-cough-and-cold-medicine-india)

---

### ðŸ‡ºðŸ‡¸ Drug Alerts and Statements

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 15:01
- **é‡è¦æ€§**: â­â­

> FDA Drug Alerts and Statements

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements)

---

### ðŸ‡ºðŸ‡¸ FDA Announces PreCheck Implementation Roadmap

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 15:00
- **é‡è¦æ€§**: â­â­

> The U.S. Food and Drug Administration announced that it will begin accepting applications on Feb. 1, 2026 for the PreCheck Pilot Program, a program to strengthen the domestic pharmaceutical supply chain. Learn more.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-precheck-implementation-roadmap)

---

### ðŸ‡ºðŸ‡¸ C3TI Compass (Knowledge Repository)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:46
- **é‡è¦æ€§**: â­

> Centralized knowledge repository for clinical trial innovation

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/c3ti-compass-knowledge-repository)

---

### ðŸ‡ºðŸ‡¸ Bayesian Statistical Analysis (BSA) Demonstration Project

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:45
- **é‡è¦æ€§**: â­

> C3TI aims to increase experience in Bayesian statistical methods in simple trial settings across sponsors, CDER clinical reviewers, and CDER statisticians, including deepening an understanding of their applicability, opportunities, and challenges.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/bayesian-statistical-analysis-bsa-demonstration-project)

---

### ðŸ‡ºðŸ‡¸ Clinical Outcome Assessment (COA): Frequently Asked Questions

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 13:16
- **é‡è¦æ€§**: â­

> Clinical Outcome Assessments (COA) Frequently Asked Questions

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions)

---

### ðŸ‡ºðŸ‡¸ List of Drug Master Files (DMFs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 20:02

> The list is updated quarterly.&nbsp;Changes are made to the DMF activity status, DMF type, holder name, and subject.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-master-files-dmfs/list-drug-master-files-dmfs)

---

### ðŸ‡ºðŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 17:38

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ðŸ‡ºðŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 17:35

> Generic Drug Facilities, Sites and Organization Lists

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ðŸ‡ºðŸ‡¸ Products Claiming to "Cure" Cancer Are a Cruel Deception

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:03

> Many ads on social media and "healthy" websites claim their products can cure cancer. They cannot.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/consumers/consumer-updates/products-claiming-cure-cancer-are-cruel-deception)

---

### ðŸ‡ºðŸ‡¸ Advisory Letters

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 13:44

> Advisory Letters

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/advisory-letters)

---

### ðŸ‡ºðŸ‡¸ Novel Drug Approvals for 2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:45

> Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)

---

### ðŸ‡ºðŸ‡¸ Drug Trials Snapshots KYGEVVI

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:43

> Drug Trials Snapshots KYGEVVI

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kygevvi)

---

### ðŸ‡ºðŸ‡¸ Compounding Quality Center of Excellence | Instructor-Led Trainings

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 21:32

> The Compounding Quality Center of Excellenceâ€™s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/compounding-quality-center-excellence/compounding-quality-center-excellence-instructor-led-trainings)

---

### ðŸ‡ºðŸ‡¸ Quality and Regulatory Predictability: Shaping USP Standards - 12/11/2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 16:26

> This discussion will show how USP public standards strengthen quality, streamline development, support regulatory compliance, and overall, increase regulatory predictability for drugs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/quality-and-regulatory-predictability-shaping-usp-standards-12112025)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ðŸ‡ºðŸ‡¸ ErVimmune raises 17m euros in funding to develop cancer vaccine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 14:10
- **é‡è¦æ€§**: â­â­

> The vaccine could be created as a ready-to-use product, rather than needing to be personalised

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/)

---

### ðŸ‡ºðŸ‡¸ Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:34
- **é‡è¦æ€§**: â­â­

> Decision introduces zolbetuximab for eligible patients in NHS Scotland

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/)

---

### ðŸ‡ºðŸ‡¸ AAX Biotech and Vascurie announce new neuro-oncology collaboration

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:41
- **é‡è¦æ€§**: â­

> The collaboration will help to advance a pipeline of antibody candidates

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/)

---

### ðŸ‡ºðŸ‡¸ Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:42
- **é‡è¦æ€§**: â­

> Company prepares marketing submission after treatment shows strong efficacy

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/nxera-pharma-reports-positive-results-from-phase-3-insomnia-trial-in-south-korea/)

---

### ðŸ‡ºðŸ‡¸ Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 12:36

> The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/)

---

### ðŸ‡ºðŸ‡¸ Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:13

> More than 71% of patients treated with Unloxcyt achieved disease control

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/)

---

### ðŸ‡ºðŸ‡¸ Peter Llewellyn-Davies

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:02

> ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/appointments/peter-llewellyn-davies/)

---

### ðŸ‡ºðŸ‡¸ Venner Shipley announces opening of new Bristol office

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:42

> The firm already has a number of offices across the UK and Europe

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-23 03:41:02*